BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20564326)

  • 21. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on bone mineral density, serum lipoproteins, hemoglobin, prostate specific antigen and sexual function in healthy young men.
    Amory JK; Anawalt BD; Matsumoto AM; Page ST; Bremner WJ; Wang C; Swerdloff RS; Clark RV
    J Urol; 2008 Jun; 179(6):2333-8. PubMed ID: 18423697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
    Shao TC; Li H; Ittmann M; Cunningham GR
    J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride.
    Byrns MC; Mindnich R; Duan L; Penning TM
    J Steroid Biochem Mol Biol; 2012 May; 130(1-2):7-15. PubMed ID: 22265960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell lines.
    Biancolella M; Valentini A; Minella D; Vecchione L; D'Amico F; Chillemi G; Gravina P; Bueno S; Prosperini G; Desideri A; Federici G; Bernardini S; Novelli G
    Invest New Drugs; 2007 Oct; 25(5):491-7. PubMed ID: 17636412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model.
    Eggener SE; Stern JA; Jain PM; Oram S; Ai J; Cai X; Roehl KA; Wang Z
    Prostate; 2006 Apr; 66(5):495-502. PubMed ID: 16372330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract.
    George FW
    Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
    Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
    Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dutasteride and enzalutamide synergistically suppress prostate tumor cell proliferation.
    Hamid AR; Verhaegh GW; Smit FP; van Rijt-van de Westerlo C; Armandari I; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
    J Urol; 2015 Mar; 193(3):1023-9. PubMed ID: 25242390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
    Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
    Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene expression in prostate cancer cells treated with the dual 5 alpha-reductase inhibitor dutasteride.
    Schmidt LJ; Murillo H; Tindall DJ
    J Androl; 2004; 25(6):944-53. PubMed ID: 15477368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.
    Tuttle RM; Loop S; Jones RE; Meikle AW; Ostenson RC; Plymate SR
    Prostate; 1994 May; 24(5):229-36. PubMed ID: 8170835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer.
    Nnane IP; Kato K; Liu Y; Lu Q; Wang X; Ling YZ; Brodie A
    Cancer Res; 1998 Sep; 58(17):3826-32. PubMed ID: 9731491
    [TBL] [Abstract][Full Text] [Related]  

  • 37. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.
    Jin RJ; Wang Y; Masumori N; Ishii K; Tsukamoto T; Shappell SB; Hayward SW; Kasper S; Matusik RJ
    Cancer Res; 2004 Aug; 64(15):5489-95. PubMed ID: 15289359
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry.
    Upreti R; Naredo G; Faqehi AM; Hughes KA; Stewart LH; Walker BR; Homer NZ; Andrew R
    Talanta; 2015 Jan; 131():728-35. PubMed ID: 25281165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of 4MA, a potent inhibitor of 5 alpha-reductase, on the growth of androgen-responsive human genitourinary tumors grown in athymic nude mice.
    Andriole GL; Rittmaster RS; Loriaux DL; Kish ML; Linehan WM
    Prostate; 1987; 10(3):189-97. PubMed ID: 3588410
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
    Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
    PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.